Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00327743 · ClinicalTrials.gov registry record · Phase 1
Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer
A Phase 1 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00327743 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 34 participants.
The verdict
NCT00327743, a Phase 1 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The goal of this phase I-II clinical research study is to find the highest safe dose of XRP9881 and capecitabine that can be given in combination in the treatment of metastatic breast cancer in patients who have been previously treated by taxanes and anthracyclines. The safety and effectiveness of this combination will also be studied. Patients participating in the study will be asked to give additional blood samples to look at the level of study drugs in the blood.
Interventions
- DRUG capecitabine
- DRUG larotaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2006-08 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00327743
The ClinicalTrials.gov registry entry for NCT00327743 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which capecitabine is the first listed.
NCT00327743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00327743 about?
NCT00327743 is a clinical study titled "Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer". The goal of this phase I-II clinical research study is to find the highest safe dose of XRP9881 and capecitabine that can be given in combination in the treatment of metastatic breast cancer in patients who have been previously treated by taxanes and anthracyclines. The safety and effectiveness of t...
What is the current status of trial NCT00327743?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2006-08. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00327743?
The interventions under investigation include: capecitabine (DRUG), larotaxel (DRUG).
Who is sponsoring clinical trial NCT00327743?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.